Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

Gastrointestinal Malignancies Clinical Trial

Official title:

A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05229588
• Other study ID #: HRI-Lurbinectedin-001
• Status: Recruiting
• Phase: Phase 2
• Start date: June 14, 2022
• Est. completion date: August 31, 2026

Study information

• Verified date: February 2024
• Source: HonorHealth Research Institute
• Contact: Erkut Borazanci, MD
• Phone: 480-323-1364
• Email: clinicaltrials[@]honorhealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 19
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Voluntary written informed consent form (ICF) of the patient obtained before any study-specific procedure.

• Age = 18 years of age; male or female.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score =1

• Histologically or cytologically confirmed gastrointestinal carcinoma

• Locally advanced unresectable or metastatic disease at study entry

• Known deleterious or suspected deleterious (or equivalent interpretation) mutations in DNA repair in ATM, ATR, CHEK2, BRCA1, BRCA2, RAD51, BRIP1, PALB2, PTEN, FANC, NBN, EMSY, MRE11, or ARID1A prior to study entry

• Progressive disease to prior treatment. Patients no longer able to continue prior treatment due to intolerable toxicity may be considered for study participation provided that radiology assessment confirms either stable disease or disease progression (i.e., no response to treatment).

• Measurable tumor lesions according to RECIST 1.1 criteria.

• Adequate hematological, renal, metabolic and hepatic function, defined as:

1. Hemoglobin =9 g/dL (patients may have received prior red blood cell [RBC] transfusion, if clinically indicated); absolute neutrophil count (ANC) =1.5 x 109/L, and platelet count =100 x 109/L.

2. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =3.0 x upper limit of normal (ULN).

3. Total bilirubin = ULN.

4. Albumin =3.0 g/dL.

5. Calculated creatinine clearance (CrCL) =30 mL/min (according to the Cockcroft and Gault´s formula).

• 11. Washout periods prior to Day 1 of Cycle 1:

1. At least three weeks since last prior chemotherapy and/or investigational drugs.

2. At least four weeks since the last radiotherapy (RT) > 30 Gy.

3. At least two weeks since the last palliative RT (= 10 fractions or = 30 Gy total dose).

• Patients with prior malignancy successfully treated who are currently stable and on no active treatment are eligible.

• Recovery to grade =1 from any adverse event (AE) derived from previous anticancer treatment (excluding alopecia and/or skin toxicity of any grade and grade =2 peripheral neuropathy) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.5).

• Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure* during the trial and up to six weeks after treatment discontinuation, and fertile male patients with WOCBP partners must agree to refrain from fathering a child or donating sperm during the trial and up to four months after treatment discontinuation.

• Highly effective methods: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence

Exclusion Criteria:

• Prior treatment with lurbinectedin or trabectedin

• Neuroendocrine differentiation subtype in histology

• More than three prior systemic chemotherapy lines for advanced disease

• Known brain metastases or leptomeningeal disease involvement

• Concomitant diseases/conditions:

1. History of cardiac disease: myocardial infarction or symptomatic/uncontrolled angina within the year prior to enrollment; or pain history of left ventricular ejection fraction (LVEF) = 50% assessed by multiple-gated acquisition scan (MUGA) or equivalent by ultrasound (US); or symptomatic arrhythmia.

2. Generalized edema, and/or ascites clinically evident or requiring drainages within three weeks prior to study entry. Permanent external drainages due to ascites are also excluded.

3. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV).

4. Known chronically active hepatitis B virus (HBV) or hepatitis C virus (HCV). For hepatitis B, this includes positive tests for both hepatitis B surface antigen and quantitative hepatitis B polymerase chain reaction (PCR). For hepatitis C, this includes positive tests for both hepatitis C antibody and quantitative hepatitis C PCR.

5. Active uncontrolled infection.

6. Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.

7. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.

• Patients acutely ill and/or in immediate vital distress, including those with rapidly deteriorating clinical condition or who may require unscheduled hospitalizations due to uncontrolled disease symptoms within the prior two weeks to treatment registration.

• Pregnant or breastfeeding women.

• Live vaccine administration within 3 weeks of study entry

Related Conditions & MeSH terms

• Gastrointestinal Malignancies
• Neoplasms

Intervention

Drug:
• Lurbinectedin 4 MG Injection [Zepzelca]
Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride). Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate.

Locations

Country	Name	City	State
United States	HonorHealth Research Institute	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
HonorHealth Research Institute	Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the antitumor activity	To evaluate the antitumor activity of Lurbinectedin in terms of overall response rate (ORR), according to RECIST v.1.1, in patients with advanced pancreatic cancer with DNA repair mutations.	Initiation of study treatment up to 10 cycles (each cycle is 21 days ± 48 hours)
Secondary	Duration of response (DOR)	Duration of response (DOR), defined as the time from the date when the response criteria (PR or CR) are fulfilled to the date of PD, recurrence or death.	Initiation of study treatment up to study completion, up to 2 years
Secondary	Clinical benefit	Clinical benefit, defined as the percentage of patients with ORR or SD =4 months, according to RECIST v.1.1.	Initiation of study treatment up to study completion, up to 2 years
Secondary	Measure amount of CA19-9, CEA, or CA125	Measure amount of CA19-9, CEA, or CA125 (whichever is being followed) in blood during treatment.	Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)
Secondary	Progression-free survival (PFS)	Progression-free survival (PFS), defined as the time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation.	Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)
Secondary	Progression-free survival rate at three months (PFS3)	Progression-free survival rate at three months (PFS3), defined as the percentage of patients who are alive and progression-free three months after the first infusion.	Initiation of study treatment up to three months after the first infusion
Secondary	Overall survival (OS)	Overall survival (OS), defined as the time from the date of first infusion to the date of death (of any cause) or last patient contact.	Initiation of study treatment up to 2 years
Secondary	Overall survival rate at six months (OS6)	Overall survival rate at six months (OS6), defined as the percentage of patients who were alive six months after the first infusion	Initiation of study treatment up to six months after the first infusion
Secondary	Overall survival rate at 12 months (OS12)	Overall survival rate at 12 months (OS12), defined as the percentage of patients who were alive 12 months after the first infusion	Initiation of study treatment up to 12 months after the first infusion
Secondary	Treatment safety	Treatment safety: AEs, serious AEs (SAEs) and laboratory abnormalities graded according to the NCI-CTCAE v.5	Initiation of study treatment up to 2 years